Interés Humano

El lucrativo mercado de los medicamentos contra la obesidad

Si la prevención y la atención médica no mejora, la Federación Mundial de la Obesidad prevé que antes de 2025 la mitad de la población mundial sufra sobrepeso

This photo provided by Food and Drug Administration shows Arena Pharmaceutical's anti-obesity pill Belviq.  The Food and Drug Administration has approved Belviq, the first new prescription drug for long-term weight loss to enter the U.S. market in over a decade. The agency cleared the pill Wednesday for adults who are obese or are overweight with at least one medical complication, such as diabetes or high cholesterol. (AP Photo/Food and Drug Administration)
This photo provided by Food and Drug Administration shows Arena Pharmaceutical's anti-obesity pill Belviq. The Food and Drug Administration has approved Belviq, the first new prescription drug for long-term weight loss to enter the U.S. market in over a decade. The agency cleared the pill Wednesday for adults who are obese or are overweight with at least one medical complication, such as diabetes or high cholesterol. (AP Photo/Food and Drug Administration)
‌
‌

‌

‌
‌

‌

‌